The ADC has several studies under way and we are looking for volunteers to help us learn more about memory loss. To volunteer, leave your contact information on the Join a Study page.
To learn more about studies under way, scroll down for more information or call the UT Southwestern Memory Research Unit at 214-648-0563.
Study participants like Dewayne Nash, M.D., (see video below) have found that participating in our clinical trials has helped him in ways he never expected.
Observational and Biomarker Development Studies
CORE AND TARCC RESEARCH STUDIES
People with no memory complaint, mild cognitive impairment (MCI), or early Alzheimer’s disease (AD) are needed for observational studies. The studies usually involve one visit a year for neuropsychological testing, neurological exams, brain imaging, and blood sampling. The data collected from these visits are used by many investigators studying the aging brain and disorders of cognitive function. These visits may involve financial compensation. Call 214-648-0563 for more information.
LOAD (LATE-ONSET-ALZHEIMER’S DISEASE GENETICS INITIATIVE)
The LOAD study began enrolling subjects in 2002, with more than 500 subjects enrolled through UT Southwestern. A new grant, based on previous findings from that study, is facilitating a phone follow-up for subjects from the first study as well as enrolling new subjects.
The goal of this national study is to expand upon the scope of data gathered from subjects already enrolled in the first phase of LOAD as well as to enroll new large families (with three or more living siblings age 60 or older) diagnosed with Alzheimer’s disease. The focus is to learn more about the genetic, environmental, and health risks that may contribute to the development of Alzheimer’s. For all subjects previously enrolled in the LOAD study, the coordinator will call each person for phone follow-up only. New subjects from previously participating families who are now age 50 or older may also enroll in this study. Call Kasia Harrah at 214-648-9118 for more information.
A4 – ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC AD
The A4 study is for individuals aged 65-85 who have normal thinking and memory function but who have evidence of amyloid plaque build-up in their brains and who may be at risk for developing Alzheimer's disease (AD) memory loss in the future. A4 is a ground-breaking trial that will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of delaying or preventing memory and cognitive decline. Please call Erica Adkins, 214-648-9343, for more details.
COMING EARLY 2016
BIOGEN – A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADUCANUMAB (BIIB037) IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE
The purpose of this study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as compared with placebo, for persons with mild cognitive impairment (MCI) due to Alzheimer’s Disease (AD). Each participant will need a study partner – someone who is close to them, such as a family member or close friend – to attend certain study visits and provide information to the study team. You may be able to take part in this study if you have a study partner, are 50–85 years of age, and are experiencing symptoms that might be related to mild Alzheimer’s disease, such as problems with memory or thinking clearly. Please call Zohre German at 214-648-2952 for more information about this study.